{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:50:59Z","timestamp":1763016659148},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,6,21]],"date-time":"2006-06-21T00:00:00Z","timestamp":1150848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2006,6,21]],"date-time":"2006-06-21T00:00:00Z","timestamp":1150848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1007\/s10637-006-9035-2","type":"journal-article","created":{"date-parts":[[2006,6,21]],"date-time":"2006-06-21T13:31:16Z","timestamp":1150896676000},"page":"509-514","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Phase I\/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS)"],"prefix":"10.1007","volume":"24","author":[{"given":"Revathi","family":"Suppiah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Elson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George T.","family":"Budd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,6,21]]},"reference":[{"key":"9035_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","volume":"54","author":"A Jemal","year":"2004","unstructured":"Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8\u201329","journal-title":"CA Cancer J Clin"},{"key":"9035_CR2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.1999.17.1.150","volume":"17","author":"M Van Glabbeke","year":"1999","unstructured":"van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T (1999) Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens\u2014a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17:150\u2013157","journal-title":"J Clin Oncol"},{"key":"9035_CR3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/1040-8428(94)00146-K","volume":"20","author":"J Verweij","year":"1995","unstructured":"Verweij J, Mouridsen HT, Nielssen OS, Woll PJ, Somers R, van Oosterom AT, Van Glabbeke M, Tursz T (1995) The present state of the art in chemotherapy for soft tissue sarcomas in adults: The EORTC point of view. Crit Rev Oncol Hematol 20:193\u2013201","journal-title":"Crit Rev Oncol Hematol"},{"key":"9035_CR4","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1993.11.7.1269","volume":"11","author":"JH Edmonson","year":"1993","unstructured":"Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, Parkinson DR (1993) Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11:1269\u20131275","journal-title":"J Clin Oncol"},{"key":"9035_CR5","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1200\/JCO.1993.11.7.1276","volume":"11","author":"K Antman","year":"1993","unstructured":"Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, Doroshow JH, Aisner J, Pugh RP, Weiss RB, Cooper BA, Clamond GH, Baker LH (1993) An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11:1276\u20131285","journal-title":"J Clin Oncol"},{"key":"9035_CR6","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.1987.5.6.840","volume":"5","author":"EC Borden","year":"1987","unstructured":"Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, Lerner HJ, Carbone PP (1987) Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 5:840\u2013850","journal-title":"J Clin Oncol"},{"key":"9035_CR7","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2000.18.10.2081","volume":"18","author":"J Verweij","year":"2000","unstructured":"Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, Seynaeve C, Di Paola ED, Van Glabbeke M, Tonelli D, Judson IR (2000) Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 18:2081\u20132086","journal-title":"J Clin Oncol"},{"key":"9035_CR8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/oxfordjournals.annonc.a058909","volume":"5","author":"QG Van Hoesel","year":"1994","unstructured":"van Hoesel QG, Verweij J, Catimel G, Clavel M, Kerbrat P, van Oosterom AT, Kerger J, Tursz T, van Glabbeke M, Van Pottelsberghe C (1994) Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 5:539\u2013542","journal-title":"Ann Oncol"},{"key":"9035_CR9","first-page":"121","volume":"149","author":"A Amodio","year":"1998","unstructured":"Amodio A, Carpano S, Paoletti G, Gionfra T, Rinaldi M, Manfredi C, Foggi P, Lopez M (1998) Phase II study of docetaxel in patients with advanced stage soft tissue sarcoma. Clin Ter 149:121\u2013125","journal-title":"Clin Ter"},{"key":"9035_CR10","unstructured":"Baker LH, Hirth JS, Carson E, Little R, Watkins PB (1998) Cytochrome P4503A activity as a predictor of docetaxel toxicity and response. Proc Am Soc Clin Oncol 718"},{"key":"9035_CR11","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1023\/A:1012272007146","volume":"12","author":"WJ Kostler","year":"2001","unstructured":"Kostler WJ, Brodowicz T, Attems Y, Hejna M, Tomek S, Amann G, Fiebiger WC, Wiltschke CH, Krainer M, Zielinski CC (2001) Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial. Ann Oncol 12:1281\u20131288","journal-title":"Ann Oncol"},{"key":"9035_CR12","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/00000421-199612000-00008","volume":"19","author":"JH Edmonson","year":"1996","unstructured":"Edmonson JH, Ebbert LP, Nascimento AG, Jung SH, McGaw H, Gerstner JB (1996) Phase II study of docetaxel in advanced soft tissue sarcomas. Am J Clin Oncol 19:574\u2013576","journal-title":"Am J Clin Oncol"},{"key":"9035_CR13","first-page":"610","volume":"16","author":"K Itoh","year":"1997","unstructured":"Itoh K, Fujii H, Minami H (1997) Phase I and pharmacological study of docetaxel (Doc) combined with doxorubicin (Dox) for advanced breast cancer. Proc Am Soc Clin Oncol 16:610","journal-title":"Proc Am Soc Clin Oncol"},{"key":"9035_CR14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.1993.11.1.15","volume":"11","author":"WP Steward","year":"1993","unstructured":"Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E (1993) Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 11:15\u201321","journal-title":"J Clin Oncol"},{"key":"9035_CR15","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1002\/1097-0142(19821215)50:12<2757::AID-CNCR2820501211>3.0.CO;2-J","volume":"50","author":"DA Schoenfeld","year":"1982","unstructured":"Schoenfeld DA, Rosenbaum C, Horton J, Wolter JM, Falkson G, DeConti RC (1982) A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 50:2757\u20132762","journal-title":"Cancer"},{"key":"9035_CR16","first-page":"1825","volume":"53","author":"HM Pinedo","year":"1984","unstructured":"Pinedo HM, Bramwell VH, Mouridsen HT, Somers R, Vendrik CP, Santoro A, Buesa J, Wagener T, van Oosterom AT, van Unnik JA (1984) Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer 53:1825\u20131832","journal-title":"A study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer"},{"key":"9035_CR17","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1002\/1097-0142(19810515)47:10<2422::AID-CNCR2820471017>3.0.CO;2-Y","volume":"47","author":"GP Bodey","year":"1981","unstructured":"Bodey GP, Rodriguez V, Murphy WK, Burgess A, Benjamin RS (1981) Protected environment\u2014prophylactic antibiotic program for malignant sarcomas: Randomized trial during remission induction chemotherapy. Cancer 47:2422\u20132429","journal-title":"Cancer"},{"key":"9035_CR18","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.1995.13.7.1600","volume":"13","author":"A Le Cesne","year":"1995","unstructured":"Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J et\u00a0al. (1995) High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 13:1600\u20131608","journal-title":"J Clin Oncol"},{"key":"9035_CR19","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1200\/JCO.1997.15.6.2378","volume":"15","author":"SR Patel","year":"1997","unstructured":"Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS (1997) High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies\u2013dose-response and schedule dependence. J Clin Oncol 15:2378\u20132384","journal-title":"J Clin Oncol"},{"key":"9035_CR20","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/S0959-8049(02)00491-4","volume":"38","author":"AT van Oosterom","year":"2002","unstructured":"van Oosterom AT, Mouridsen HT, Nielsen OS, Dombernowsky P, Krzemieniecki K, Judson I, Svancarova L, Spooner D, Hermans C, van Glabbeke M, Verweij J (2002) Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 38:2397\u20132406","journal-title":"Eur J Cancer"},{"key":"9035_CR21","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1023\/A:1008386000547","volume":"9","author":"T Cerny","year":"1999","unstructured":"Cerny T, Leyvraz S, von Briel T, Kupfer A, Schaad R, Schmitz SF, Honegger P, Sessa C, Brunner J, Boddy AV (1999) Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 9:1087\u20131094","journal-title":"Ann Oncol"},{"key":"9035_CR22","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","volume":"20","author":"ML Hensley","year":"2002","unstructured":"Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 20:2824\u20132831","journal-title":"J Clin Oncol"},{"key":"9035_CR23","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1200\/JCO.2004.08.043","volume":"22","author":"KM Leu","year":"2004","unstructured":"Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K, Baker LH (2004) Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 22:1706\u20131712","journal-title":"J Clin Oncol"},{"key":"9035_CR24","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1002\/1097-0142(19940515)73:10<2506::AID-CNCR2820731009>3.0.CO;2-S","volume":"73","author":"G Rosen","year":"1994","unstructured":"Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckardt J, Holmes C, Fu YS (1994) Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 73:2506\u20132511","journal-title":"Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-006-9035-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-006-9035-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-006-9035-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-006-9035-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:18:49Z","timestamp":1678558729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-006-9035-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,21]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["9035"],"URL":"https:\/\/doi.org\/10.1007\/s10637-006-9035-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,21]]},"assertion":[{"value":"21 June 2006","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}